Low CETP Activity
0
Pipeline Programs
3
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Merck & Co.RAHWAY, NJ
1 programRelationship Between CETP Deficiency and Atherosclerosis in Patients With HyperalphalipoproteinemiaN/A
MSDIreland - Ballydine
1 programRelationship Between CETP Deficiency and Atherosclerosis in Patients With HyperalphalipoproteinemiaN/A
Sharp TherapeuticsPA - Pittsburgh
1 programRelationship Between CETP Deficiency and Atherosclerosis in Patients With HyperalphalipoproteinemiaN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Sharp TherapeuticsRelationship Between CETP Deficiency and Atherosclerosis in Patients With Hyperalphalipoproteinemia
Clinical Trials (1)
Total enrollment: 1,500 patients across 1 trials
NCT01916512Sharp TherapeuticsRelationship Between CETP Deficiency and Atherosclerosis in Patients With Hyperalphalipoproteinemia
Relationship Between CETP Deficiency and Atherosclerosis in Patients With Hyperalphalipoproteinemia
Start: Feb 20121,500 patients
N/AUnknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.